Objectives-Cystic fibrosis (CF), an autosomal recessive disease affecting the lung, pancreas, gut, liver, and reproductive tract, is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a cyclic adenosine 3′, 5′ monophosphateregulated chloride channel. The variability of disease progression among patients with CF suggests effects of genetic modifiers of disease. Beta-2 adrenergic receptors (β 2 AR), which are abundant in airway epithelial cells, accelerate the formation of cyclic adenosine 3′, 5′ monophosphate, which can modulate CFTR activity and affect smooth muscle contractility. We tested the hypothesis that genetic variants of the β 2 AR gene, which have been shown to influence receptor desensitization, are more frequent in patients than in controls.Methods-We genotyped 130 adult CF patients and 1 : 1 age-matched, sex-matched, and ethnicity-matched normal volunteers for Gly 16 Arg and Gln 27 Glu β 2 AR.Results-We found that CF patients were more likely than controls to be Gly 16 homozygotes (48 and 32%, respectively) (P < 0.01) and Glu 27 homozygotes (29 and 10%, respectively) (P < 0.01).
Conclusions-Our results, showing a higher frequency of Gly 16 and Glu 27 β 2 AR alleles in adult CF patients than in the control population, contrast with data from children with CF, who are reported to have lower frequency of Gly 16 and similar frequency of G1u 27 , and with data from young adults with CF, who showed no differences in frequencies of β 2 AR variants. The Gly 16 Glu 27 variant of β 2 AR may have properties that lead to enhanced β 2 AR function, resulting in the upregulation of CFTR activity and the improvement of CF disease.